Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains

Journal of Clinical Gastroenterology

Volumn 46, Issue SUPPL. 1, 2012, Pages

  Mogna, Luca ^a   Del Piano, Mario ^b   Deidda, Francesca ^a   Nicola, Stefania ^a   Soattini, Liliana ^c   Debiaggi, Rosaria ^c   Sforza, Filomena ^c   Strozzi, Gianpaolo ^d   Mogna, Giovanni ^d  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b Hospital Cardiology Maggiore della Carità Hospital   (Italy)

^c Probiotical SpA ^*  (Italy)

^d Probiotical SpA   (Italy)

Author keywords

Escherichia coli O157:H7; inhibitory activity; intestinal microbiota; probiotic strain

Indexed keywords

PROBIOTIC AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BIFIDOBACTERIUM; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; DIARRHEAGENIC ESCHERICHIA COLI; DRUG ANTAGONISM; ESCHERICHIA COLI; IN VITRO STUDY; LACTIC ACID BACTERIUM; LACTOBACILLUS; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS FERMENTUM; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS; STREPTOCOCCUS THERMOPHILUS;

ANIMALS; ANTIBIOSIS; BIFIDOBACTERIUM; COLONY COUNT, MICROBIAL; ESCHERICHIA COLI; ESCHERICHIA COLI O157; HUMANS; INTESTINES; LACTOBACILLUS; PROBIOTICS; SEROTYPING;

EID: 84866249593     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31826852b7     Document Type: Article

References (30)

1. Nazef L, Belguesmia Y, Tani A, et al. Identification of lactic acid bacteria from poultry feces: evidence on anti-Campylobacter and anti-Listeria activities. Poult Sci. 2008;87:329-334. (Pubitemid 351198499)
2. Vesterlund S, Karp M, Salminen S, et al. Staphylococcus aureus adheres to human intestinal mucus but can be displaced by certain lactic acid bacteria. Microbiology. 2006;152:1819-1826.
3. Shortt C. The probiotic century: historical and current perspectives. Trends Food Sci Technol. 1999;10:411-417.
4. Wallace B. Clinical use of probiotics in the pediatric population. Nutr Clin Pract. 2009;24:50-59.
5. Minocha A. Probiotics for preventive health. Nutr Clin Pract. 2009;24:227-241.
6. Verna EC, Lucak S. Use of probiotics in gastrointestinal disorders: what to recommend? Therap Adv Gastroenterol. 2010;3:307-319.
7. Bai AP, Ouyang Q. Probiotics and inflammatory bowel diseases. Postgrad Med J. 2006;82:376-382. (Pubitemid 43945473)
8. Senok AC, Ismaeel AY, Botta GA. Probiotics: facts and myths. Clin Microbiol Infect. 2005;11:958-966. (Pubitemid 41748929)
9. Resta-Lenert S, Barrett KE. Probiotics and commensals reverse TNF-a-and IFN-g-induced dysfunction in human intestinal epithelial cells. Gastroenterology. 2006;130:731-746. (Pubitemid 43374524)
10. Shi HN, WalkerWA. Bacterial colonization and the development of intestinal defenses. Can J Gastroenterol. 2004;18:493-500. (Pubitemid 39248249)
11. Kohler H, McCormick BA, Walker WA. Bacterial-enterocyte crosstalk: cellular mechanisms in health and disease. J Pediatr Gastroenterol Nutr. 2003;36:175-185. (Pubitemid 39272966)
12. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut. 2003;52:988-997. (Pubitemid 36765291)
13. Edberg SC, Rice EW, Karlin RJ, et al. Escherichia coli: the best biological drinking water indicator for public health protection. Symp Ser Soc Appl Microbiol. 2000;29:106S-116S. (Pubitemid 30336119)
14. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308:1635-1638. (Pubitemid 40807514)
15. Leclerc H, Mossel DA, Edberg SC, et al. Advances in the bacteriology of the coliform group: their suitability as markers of microbial water safety. Annu Rev Microbiol. 2001;55: 201-234. (Pubitemid 32979158)
16. Karlin DA, Mastromarino AJ, Jones RD, et al. Fecal skatole and indole and breath methane and hydrogen in patients with large bowel polyps or cancer. J Cancer Res Clin Oncol. 1985;109:135-141. (Pubitemid 15145343)
17. Schuller HM. Nitrosamines as nicotinic receptor ligands. Life Sci. 2007;80:2274-2280. (Pubitemid 46818287)
18. Mack DR, Michail S, Wei S, et al. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol. 1999;276: G941-G950. (Pubitemid 29214108)
19. Lyte M. The biogenic amine tyramine modulates the adherence of Escherichia coli O157:H7 to intestinal mucosa. J Food Prot. 2004;67:878-883. (Pubitemid 38610911)
20. Lyte M, Arulanandam BP, Frankl CD. Production of Shigalike toxins by Escherichia coli O157:H7 can be influenced by the neuroendocrine hormone norepinephrine. J Lab Clin Med. 1996;128:392-398. (Pubitemid 27506926)
21. Jandu N, Zheng ZJ, Johnson-Henry KC. Probiotics prevent enterohaemorrhagic Escherichia coli O157:H7-mediated inhibition of interferon-g-induced tyrosine phosphorylation of STAT-1. Microbiology. 2009;155:531-540.
22. Serna A, Boedeker EC. Pathogenesis and treatment of Shiga toxin-producing Escherichia coli infections. Curr Opin Gastroenterol. 2008;24:38-47. (Pubitemid 350190896)
23. Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol. 2005;295:405-418. (Pubitemid 41225453)
24. Maki DG. Don't eat the spinach-controlling foodborne infectious disease. N Engl J Med. 2006;355:1952-1955. (Pubitemid 44708013)
25. Rangel JM, Sparling PH, Crowe C, et al. Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982-2002. Emerg Infect Dis. 2005;11:603-609. (Pubitemid 40462912)
26. Santini C, Baffoni L, Gaggia F, et al. Characterization of probiotic strains: an application as feed additives in poultry against Campylobacter jejuni. Int J Food Microbiol. 2010;141: S98-S108.
27. Collado MC, Isolauri E, Salminen S, et al. The impact of probiotic on gut health. Curr Drug Metab. 2009;10:68-78.
28. Corr SC, Hill C, Gahan CG. Understanding the mechanisms by which probiotics inhibit gastrointestinal pathogens. Adv Food Nutr Res. 2009;56:1-15.
29. Sá nchez B, Urdaci MC, Margolles A. Extracellular proteins secreted by probiotic bacteria as mediators of effects that promote mucosa-bacteria interactions. Microbiology. 2010;156: 3232-3242.
30. Oppega? rd C, Rogne P, Emanuelsen L, et al. The two-peptide class II bacteriocins: structure, production, and mode of action. J Mol Microbiol Biotechnol. 2007;13:210-219. (Pubitemid 47378150)